Dermapliq®

Dermapliq® is a skin hygiene product for animals. It is designed for animal skin lesions and is recommended for use on cats, dogs, sport and race horses as well as exotic animals.

Dermapliq, produit vétérinaire

Additional information from Dermapliq®

It belongs to the family of regenerating agents (RGTA®), made up of polymers synthesized from biodegradable sugars.

  • Sterile solution for external use.
  • Easy to use.
  • Box containing a 7.5 ml bottle: about 50 sprays.
  • Pump 3K® guaranteeing sterility for 6 months
  • Preservative free.

Dermapliq® is a therapeutic product based on RGTA® technology.
Dermapliq® protects extracellular matrix proteins to restore the matrix architecture. It preserves the natural cellular micro-environment of the wound and the endogenous factors necessary for tissue regeneration.

The formulation is based on an RGTA® in physiological serum to facilitate wound healing in animals.

Publications

Below is a selection of clinical publications on our product.

  • Cacipliq 20

    Cacipliq 20® - Diabetic Foot Ulcer Matrix Protection Therapy in Diabetic Foot Ulcers: Pilot Study of CACIPLIQ20® INES SLIM (MD), HOUDA TAJOURI (MD), DENIS BARRITAULT (PHD), MAHA KACEM NJAH (MD), KOUSSAY ACH (MD), MOLKA CHADLI CHAIEB MD, LARBI CHAIEB (MD) We evaluated whether matrix protection therapy by Cacipliq 20® [...]

  • Cacipliq 20

    Cacipliq 20® - Foot Ulcer Efficacy of a New Heparan Sulfate Mimetic Dressing in the Healing of Foot and Lower Extremity Ulcerations in Type 2 Diabetes: A Case Series Nikolaos Papanas, Costas Demetzos, Natassa Pippa, Efstratios Maltezos and Nicholas Tentolouris A novel heparan sulfate glycosaminoglycan mimetic product for local [...]

  • Cacipliq 20

    Cacipliq 20® - hand injury ReGeneraTing Agents (RGTA®) are a new option to improve amputation outcomes in the recovery of severe hand injuries Roohi Sharifah Ahmad and Denis Barritault Cacipliq 20® was used to accelerate the healing process and stimulate the viability of flaps and skin grafts, thereby improving [...]

Questions about OTR3 ?